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Modulation of nasopharyngeal innate defenses
by viral coinfection predisposes individuals to
experimental pneumococcal carriage
S Glennie1,6,7, JF Gritzfeld1,6, SH Pennington1, M Garner-Jones1, N Coombes1, MJ Hopkins2,
CF Vadesilho3, EN Miyaji3, D Wang4, AD Wright1,5, AM Collins1,5, SB Gordon1,8 and DM Ferreira1,8
Increased nasopharyngeal colonization density has been associated with pneumonia. We used experimental
human pneumococcal carriage to investigate whether upper respiratory tract viral infection predisposes individuals to
carriage. A total of 101 healthy subjects were screened for respiratory virus before pneumococcal intranasal challenge.
Virus was associatedwith increased odds of colonization (75%virus positive became colonized vs. 46%virus-negative
subjects; P¼ 0.02). Nasal Factor H (FH) levels were increased in virus-positive subjects and were associated with
increased colonization density. Using an in vitro epithelial model we explored the impact of increasedmucosal FH in the
context of coinfection. Epithelial inflammation and FH binding resulted in increased pneumococcal adherence to the
epithelium. Bindingwas partially blockedby antibodies targeting the FH-binding protein Pneumococcal surface protein
C (PspC). PspC epitope mapping revealed individuals lacked antibodies against the FH binding region. We propose
that FH binding to PspC in vivo masks this binding site, enabling FH to facilitate pneumococcal/epithelial attachment
during viral infection despite the presence of anti-PspC antibodies. We propose that a PspC-based vaccine lacking
binding to FH could reduce pneumococcal colonization, and may have enhanced protection in those with underlying
viral infection.
INTRODUCTION
Secondary bacterial infections with Streptococcus pneumoniae
are a major cause of morbidity and mortality during pandemic
influenza.1 Pneumococcus commonly colonizes the upper
respiratory tract (URT) in healthy individuals but viral
infections transform this normally harmless commensal
organism into a potentially fatal pathogen by increasing
pneumococcal transmission,2 carriage density,3,4 and host
disease susceptibility.5 The current threat of influenza pan-
demics, increasing antibiotic resistance, and the burden of
coinfection in the young and aged populations make it critical
to understand how viral infection increases susceptibility to
pneumococcal disease.
Pneumococcal colonization at the mucosal surface is a
prerequisite of invasive disease.6,7 Children with radiologically
confirmed pneumonia have a marked increase in the density of
colonizing pneumococci if coinfected with influenza A, respira-
tory syncytial virus, or rhinovirus.3 Several possible mechanisms
may account for increased nasopharyngeal pneumococcal
density, including influenza-induced damage to the epithelium
and/or alterations in host cellular responses to bacterial patho-
gens.8,9 Viral infections reduce mucociliary velocity, denude
epithelial surfaces and expose basement membranes, and
modulate chemokine and innate defenses.10–12
We used an experimental human pneumococcal carriage
(EHPC) model13 to investigate the relationship between
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asymptomatic URT viral infections and pneumococcal colo-
nization in humans. Experimental carriage offers a unique
opportunity to investigate mucosal responses14,15 in a setting
where the onset and termination as well as density of
pneumococcal carriage episodes are known.16,17
In this study, we hypothesized that subjects with an
asymptomatic URT viral infection would be more susceptible
to pneumococcal carriage acquisition and/or would have
increased carriage density. We observed that virus was
associated with a 2.8-fold increase in the odds of becoming
colonized after experimental inoculation. We then investigated
a possible mechanism by which virus could modulate mucosal
defenses and increase colonization. We measured levels of
several soluble innate factors at the nasal mucosa and observed
that levels of human Factor H (FH) were increased in subjects
coinfected with virus and pneumococcus.
FH is a soluble protein found in human plasma that
suppresses the alternative complement pathway.18 It is well
described that pneumococcus binds FH via Pneumococcal
surface protein C (PspC),19 facilitating adherence to epithelial
cells.20 PspC also interacts with the human polymeric
immunoglobulin (Ig) receptor to promote bacterial adherence
to, and invasion of, epithelial cells, as well as binding to the
secretory component of immunoglobulin A (IgA).21 As a result
of these important interactions with the host immune system,
PspC has been proposed as a vaccine candidate to block
pneumococcal carriage.22 The process of FH-mediated adher-
ence and uptake of pneumococci has been described. The first
and initial contact of FH-coated pneumococci is mediated by
glycosaminoglycans expressed on the surface of human cells,
and the second step, pneumococcal uptake, is integrinmediated
and depends on host signaling molecules such as phospha-
tidylinositol 3-kinase.23 In this study we found that a doubling
in nasal FH levels was associated with a 9.3 times increase in the
odds of carriage and a 4.26 times increase in the geometricmean
of carriage density.
We investigated whether nasal wash fluid containing FH
would influence bacterial adherence. FH binding to pneumo-
coccus resulted in greater in vitro epithelial adherence, an effect
that was partially reduced by purified human anti-PspC
antibodies. To explore the reasons behind this partial reduction,
we mapped PspC epitopes and revealed that adults lack anti-
PspC antibodies that recognize the FH binding site. Our results
suggest that blocking the PspC–FH interaction with a mucosal
vaccine could potentially reduce colonization density and the
viral-associated pneumococcal disease burden.
RESULTS
Asymptomatic URT viral infections increased
susceptibility to pneumococcal colonization
A total of 101 healthy subjects (age 18–50 years) were
challenged with pneumococcus between November 2011
and April 2014. The average age (mean±s.d.) of subjects
was 23±6 years and 38% were male (38/101). Oropharyngeal
swabs taken 5 days before challenge were analyzed by PCR for
the presence of URT viruses. Nasal wash samples were taken 2,
7, and 14 days after inoculation and analyzed for the presence of
pneumococcal carriage by classicalmicrobiology. Experimental
carriage of 6B pneumococcus was detected in 52 out of 101
subjects (51%), as defined by the presence of pneumococci in
nasal wash at any time point after challenge.
We investigated whether the presence of virus predisposed
certain individuals to colonization. There were no significant
differences between virus-positive and virus-negative subjects
with regard to age (22±3 vs. 23±7 years,P¼ 0.5), gender (M/F
6:14 vs. 32:49, P¼ 0.6), or inoculation dose (P¼ 0.8). Among
virus-positive subjects, 75% became colonized (15/20) as
compared with 46% virus-negative subjects (37/81) (P¼ 0.02;
Figure 1a). We could not find an association between the
presence of virus and increased density (Figure 1b) or duration
of 6B colonization (data not shown). Only infections caused by
a single virus were detected. The detected viruses among
Figure 1 Asymptomatic upper respiratory tract (URT) viral infections are
associated with susceptibility to pneumococcal colonization but not
increased density. (a) A total of 101 healthy subjects were screened for
URT viruses by multiplex PCR 5 days before intranasal inoculation of 6B
pneumococcus. The percentage of carriage-positive (carriers) and
carriage-negative (noncarriers) subjects are shown for virus negative or
virus positive. Among virus-positive subjects, 75% became colonized as
compared with 46% virus-negative subjects (P¼0.02, using Fisher’s
exact test). (b) Colonization density recovered from the nasopharynx was
measured in nasal wash samples collected 2, 7, and 14 days following
pneumococcal inoculation and is expressed as CFUml 1 recovered from
nasal wash (NW) of virus-negative (no virus) and virus-positive (virus)
groups. There was no difference in colonization density between virus-
positive and virus-negative subjects. CFU, colony-forming unit; neg,
negative; pos, positive.
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colonized subjects were rhinovirus (8/15), coronavirus (4/15),
respiratory syncytial virus (2/15), and parainfluenza virus
(1/15); similarly, noncolonized individuals were positive for
rhinovirus (3/5), coronavirus (1/5), and adenovirus (1/5).
Levels of mucosal FH were increased in individuals
coinfected with virus and pneumococci and associated
with increased colonization density
We investigated levels of mucosal FH, secretory leukocyte
proteinase inhibitor (SLPI), b-defensin 2, and lactoferrin in
nasal wash to determine whether modulation of these innate
factors by a virus could predispose individuals to pneumococcal
colonization. Levels of FH (Figure 2a) were slightly higher in
the nasal wash samples of subjects coinfected with virus and
pneumococci compared with virus-only individuals (P¼ 0.04)
In contrast, levels of the antimicrobial factor SLPI (Figure 2b),
antimicrobial b-defensin 2 (Figure 2c), and lactoferrin
(Figure 2d) were not significantly different.
As virally infected individuals colonized with pneumococci
had slightly high levels of FH, we investigated the relationship
between FH and bacterial colonization density. We found that
individuals with high mucosal FH levels had increased 6B
colonization density (Figure 2e, P¼ 0.005).
Using a generalized estimating equation (GEE) model we
examined the association of virus presence and mucosal FH
levels, individually as well as jointly, with carriage presence and
density (Table 1). When we examined the effects of virus
presence and mucosal FH levels individually (GEE models
1 and 2), virus presence was associated with a 2.83 times
increase in the odds of becoming colonized (P¼ 0.023) and a
doubling in FH levels was associated with a 2.54 times increase
in the geometricmean of carriage density (P¼ 0.002).Whenwe
Figure 2 Levels of mucosal Factor H (FH) are increased in individuals coinfected with virus and pneumococci and correlate with colonization density.
Mucosal levels of (a) Factor H, (b) secretory leukocyte proteinase inhibitor (SLPI), (c) b-defensin 2, and (d) lactoferrin were measured in nasal wash
samples obtained2daysafter pneumococcal challengewith 6B. Levels are expressed in ngml 1 and results are stratified by pneumococcal carriageand
absence or presence of virus. Statistical differences were analyzed using unpaired Student’s t-test (*Pr0.05). (e) We observed a positive correlation
between levels of FH and pneumococcal colonization density (CFUml1) recovered from nasal wash (NW) 2 days after inoculation using Pearson’s
correlation test. CFU, colony-forming unit. P-value and the correlation coefficient (r) are presented.
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examined their effects jointly (GEE model 3), we found an
interaction. Specifically, among virus positives a doubling in FH
levels was associated with a 9.33 times increase in the odds of
carriage (P¼ 0.034) and a 4.26 times increase in the geometric
mean of carriage density (P¼ 0.009).
Nasal wash fluid and epithelium inflammation increased
pneumococcal adherence and internalization
Weused amodel of noninflamed and inflamed nasopharyngeal
epithelium to investigate the role of mucosal FH in pneumo-
coccal adherence during health and coinfection, respectively.
Inflammation of epithelium was confirmed by increased
expression of polymeric immunoglobulin receptor and the
receptor for platelet-activating factor (data not shown). We
observed more than twofold increase in pneumococcal
adherence of D39 to inflamed epithelium compared with
noninflamed epithelium (Figure 3a, black squares).
We tested whether either pure FH or nasal wash containing
FH would influence bacterial adherence. Pneumococcal IgA1
protease cleaves IgA1 antibodies found in nasal wash15 and
promotes pneumococcal adherence.24 Because of this impor-
tant mechanism we used nasal wash samples depleted of IgA or
IgG. Pretreatment of bacteria with pure FH increased D39
pneumococcal adherence to noninflamed and inflamed epithe-
lium (Figure 3a, open dots) and adherence was dependent on
PspC expression (Figure 3b). Pretreatment of bacteria with
nasal wash samples depleted of IgA (Figure 3a, gray dots) or
IgG (Figure 3a, black dots) equally increased pneumococcal
adherence to nasopharyngeal cells, and this effect was
independent of PspC expression (Figure 3b). We observed
increased internalization of bacteria when pretreated with FH
(Figure 3c, open dots), nasal wash IgA depleted (Figure 3c,
gray dots), or nasal wash IgG depleted (Figure 3c, black dots).
This effect was more marked when the epithelium was
inflamed.
Anti-PspC IgG partially blocked FH binding to
pneumococcus and pneumococcal adherence and
internalization to pharyngeal cells
We investigated whether anti-PspC antibodies purified from
individuals participating in the EHPC model could block FH
binding to pneumococcus in vitro and circumvent the increased
adherence of pneumococcus during inflammation. The specific
binding of FH via PspC to our laboratory strain was confirmed
(Supplementary Figure S1A,B online). Anti-PspC antibodies
were isolated from serum where they are more abundant than
in nasal wash. Flow cytometric analysis indicated that samples
from each subject had anti-PspC IgG that bound effectively to
pneumococcus (Figure 4a, P¼ 0.01 using unpaired t-test).
Levels of IgG binding were variable among samples and related
to anti-PspC IgG levels measured by enzyme-linked immuno-
sorbent assay (ELISA; Supplementary Figure S1C). Purified
samples also had measurable levels of FH remaining after the
anti-PspC IgG purification process (Supplementary Figure
S1C). Purified samples were incubated with bacteria before
addition of FH in order to block PspC–FH interaction. We
observed a partial inhibition of FH binding to pneumococcus
by purified human anti-PspC IgG samples (Figure 4b).
We then investigated whether purified anti-PspC IgG could
block pneumococcal adherence and internalization to host
epithelial cells. Epithelial adherence was reduced by purified
anti-PspC IgG (Figure 4c, gray dots) containing 3.5 mgml 1 of
residual FH (residual from anti-PspC purification process,
Supplementary Figure S1C) but not in the presence of higher
levels of FH (20 mgml 1; Figure 4c, open dots). This interac-
tion was specific to PspC as treatment with anti-PspC IgG did
not alter adherence of D39 DPspC (Figure 4d, gray dots).
Internalization of D39 was inhibited by anti-PspC IgG
(Figure 4e, gray dots) but not by purified total IgG (open
squares).
Anti-PspC epitope mapping revealed lack of human
antibodies recognizing the binding site for FH after
intranasal exposure to pneumococcus
To explore reasons for the inefficient blocking of the FH–
pneumococcus interaction by anti-PspC IgG, we used peptide
arrays to define the epitopes of PspC recognized by human
antibodies. We used serum from 18 healthy adults challenged
with pneumococcus to probe peptide arrays containing the entire
sequence of PspC group 3 (PspC3, 491/00 strain). We observed
that despite high levels of anti-PspC antibodies, only 1 out of
the 29 samples had antibodies recognizing the binding sites for
FH (Figure 5) that supports the partial inhibition of FH bind-
ing to pneumococcus observed in vitro (Figure 4b). Secretory
IgA binding sites were recognized by all samples (Figure 5).
Table 1 Association of virus presence and mucosal factor H levels with carriage presence and carriage density
Modela Variableb Carriage presence
(OR (95% CI))
P-value Carriage density
(OR (95% CI))
P-value
Model 1 Virus status (positive vs. negative) 2.83 (1.15–6.96) 0.023 0.96 (0.43–2.17) 0.930
Model 2 Factor H levels (ngml 1) 1.95 (0.82–4.64) 0.133 2.54 (1.43–4.51) 0.002
Model 3 Factor H levels (ngml 1) among virus negative 1.20 (0.43–3.34) 0.727 2.36 (1.06–5.25) 0.035
Factor H levels (ngml 1) among virus positive 9.33 (1.19–73.31) 0.034 4.26 (1.43–12.68) 0.009
Abbreviations: CI, confidence interval; OR, odds ratio.
aGeneralized estimating equation model was used for the data analysis. Model 1 has virus status (positive and negative) and day (days 2, 7, and 14) as predictors; model 2 has
Factor H levels in log scale and day as predictors; Model 3 has Factor H levels and virus status, day, and interaction between Factor H levels and virus as predictors.
bFactor H levels are in log scale.
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PspC–FH binding is specific to humans and does not occur
in mice.25,26 We repeated the peptide arrays using sera from
mice immunized with PspC3 to test the hypothesis that PspC
would not be masked by binding of FH and therefore mice
would produce antibodies against this region. We found that
sera from immunized mice recognized the binding site for FH
aswell as all the other peptides already identified by human sera
(Supplementary Figure S2). These findings support our
previous results and suggest that PspC–FH is an important
interaction that occurs in the nasopharynx during pneumo-
coccal colonization.
DISCUSSION
S. pneumoniae has evolved several strategies to adhere to host
cells and evade host complement and immune attack. We have
shown that virus coinfection is associated with three times
increased odds of becoming colonized. In the presence of virus,
mucosal levels of FH are increased and this may partly
explain the predisposition of virally infected individuals to
pneumococcal carriage in our EHPC model. Increased FH
levels were also associated with increased carriage density.
Our results corroborate previous reports showing that
carriage isolates presented greater binding to FH than systemic
isolates,27 supporting the relevance of the pneumococcus–FH
interaction at the upper airway. However, we could not observe
a correlation between viral coinfection and increased coloniza-
tion density. This is in contrast to findings recently published by
Wolter et al.,28 who found a relationship between increased
pneumococcal colonization density and respiratory virus
coinfection in South Africans being treated for acute lower
respiratory tract infection. This could be the result of differ-
ences in recruitment; our study included healthy, asympto-
matic adults, whereas the South African study recruited
hospitalized individuals of any age, including 41% who were
o2 years old and 51% who were HIV positive.
Using a GEE model we found an interaction between virus
presence, susceptibility to colonization, increased colonization
density, and increased FH levels. This is the first time that
Figure 3 Pneumococcal epithelial adherence and internalization are increased in the presenceof humannasal wash (NW)orFactorH (FH). Adherence
of (a) D39 and (b) D39DPspC to human pharyngeal epithelial cells (Detroit 562) was evaluated in noninflamed and inflamed epithelium. PspC,
Pneumococcal surface protein C. (a) Epithelial adherence and (c) internalization of pneumococci was increased following treatment of bacteria with
human purified FH (open dots), NW depleted of IgA (gray dots), and NW depleted of IgG (black dots) when compared with untreated bacteria (black
squares). (b) Epithelial adherence was not increased when D39DPspC was pretreated with FH (open dots). All conditions were performed in duplicate
and experiments were repeated at least twice. For each experiment, the average recovered colony-forming units (CFUs) from the control condition
(adherence of D39 untreated bacteria to noninflamed cells) was used to calculate fold change of all remaining conditions. The symbol þ represents
statistical significance compared with control condition using unpaired t-test (þPr0.05 and þ þPr0.005). The symbol * represents statistical
significance compared with untreated bacteria of same epithelial condition using unpaired Student’s t-test (*Pr0.05 and **Pr0.005).
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Figure 4 Purified human anti-PspC immunoglobulin G (IgG) binds to pneumococcus and partially inhibits Factor H (FH) binding and adherence to
human pharyngeal epithelial cells. (a) We measured anti-PspC IgG binding to D39 and (b) inhibition of FH binding by purified anti-PspC IgG. PspC,
Pneumococcal surface protein C. Each row represents one subject. Negative controls (without anti-PspC or FH) are represented by unfilled histograms
(a, b). For the inhibition of FH assay the positive control (without anti-PspC andwith FH) is represented by black filled histogram. (c) Epithelial adherence
of D39 was evaluated following treatment of bacteria with purified anti-PspC IgG containing low levels of FH (3.5 mgml1 residual from purification
of serum samples, gray dots) or with anti-PspC IgG before addition of high levels of FH (10 mgml1, open dots) and compared with untreated bacteria.
(d) Adherence of D39DPspC untreated (black squares) or treatedwith purified anti-PspC IgG (gray dots) was evaluated. (e) D39 epithelial internalization
wasmeasured in untreated bacteria (black squares) and bacteria treatedwith the purified anti-PspC IgG (gray dots) or the total IgGpurified from the same
serum samples as control for antibody specificity (open squares). The symbol þ represents statistical significance comparedwith control condition using
unpaired t-test (þPr0.05 and þ þPr0.01). The symbol ** represents statistical significance compared with untreated bacteria on inflamed epithelial
condition (black squares) using unpaired t-test (*Pr0.05 and **Pr0.005).
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asymptomatic URT viral infection has been directly associated
with increased pneumococcal colonization and increased
mucosal FH levels in healthy adults.
We were unable to detect FH expression in epithelial cells
after in vitro stimulation of nasal wash samples containing virus
(data not shown). Previous transcriptome of epithelial cells
Figure 5 Pneumococcal surface protein C (PspC) epitope mapping using sera of healthy adults exposed to pneumococcus reveals the lack of
antibodies to the Factor H (FH) binding site. The amino acid sequence of PspC group 3 variant was spotted on peptide arrays and is represented on the x
axis. Peptide arrays covering the N-terminal region until the proline-rich region were probed with 29 samples from 18 subjects. The number of samples
that recognized each peptide is represented on the y axis. Sequences of the peptides recognized by human sera are in black and the ones not recognized
are in gray. Binding sites for FH and secretory immunoglobulin A (sIgA) are represented in dashed black and continuous gray boxes, respectively.
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have not found expression of the FH gene to be upregulated
after virus infection.29 It is therefore likely that increased FH
levels at the mucosa were not sourced by increased local
expression but by leakage from blood stream into the nasal
mucosa because of inflammation caused by pneumococcus
virus coinfection.12
We investigated the effect of nasal wash containing FH on
pneumococcal adherence to noninflamed and inflamed
epithelium. We observed that treatment of pneumococcus
with nasal wash containing several innate factors, including FH,
promoted increased epithelial attachment and internalization.
This effect was more pronounced when bacteria were treated
with purified human FH or the epithelium was inflamed.
We used a pneumococcal strain lacking expression of PspC
(D39 DPspC) to show that PspC mediates the effect of FH on
epithelial adherence. AlthoughD39 expresses PspC3 and the 6B
strain used for human inoculation expresses PspC9, there is
58% similarity in the N-terminal (first 110 amino acids)
between the PspC amino acid sequence of both strains. With
D39, increased adherence promoted by nasal wash was not
caused by existing FH alone in these samples. We observed no
difference in adherence when nasal wash samples depleted of
IgG or IgA were used to treat D39 DPspC and therefore the
PspC–secretory IgA interaction was not the main mechanism
for this increased adherence either. There are several pneu-
mococcal-specific host–pathogen interactions that could play a
role in epithelial attachment.30 The interaction between PspC
and vitronectin has recently been highlighted as an important
mechanism for pneumococcal adhesion.31
We hypothesize that in the presence of anti-PspC IgG and
low levels of FH, there is decreased pneumococcal adherence as
anti-PspC antibodies block adherence mediated by other
factors such as vitronectin (Figure 6, middle). FH con-
tinues to facilitate low levels of adherence because human
anti-PspC antibodies do not recognize the FH binding site.
When FH levels are high, pneumococcal adherence increases
because of more interactions between PspC and FH (Figure 6,
right). Decreased adherence caused by the binding of anti-PspC
antibodies to other factors such as vitronectin is masked by this
increase in Pspc–FH binding and adherence.
As we observed that the PspC–FH interaction was associated
with high rates and densities of carriage in humans coinfected
with virus, we tested whether antibodies to the vaccine
candidate PspC could block this interaction. PspC-based
vaccines are protective against both invasive pulmonary disease
and colonization in murine models of infection.32,33 We
observed a partial blocking of FH binding to pneumococcus by
flow cytometry analysis and epithelial adherence assay. Anti-
PspC IgG purified from serum blocked bacterial attachment
when low levels of FH were present in the assay. These results
could be explained by the fact that healthy adults do not have
antibodies specific to the PspC region that binds FH. By using
sera frommice immunized with PspC in these assays, we found
that human carriage induces anti-PspC antibodies to the same
epitopes as the ones induced by parenteral immunization with
purified protein in mice. Two major differences were that (i)
mice did not have antibodies against the proline-rich region of
PspC, although this was one of the most recognized regions by
human antibodies and (ii) human antibodies did not recognize
the binding site for FH on PspC whereas immunized mice did.
Crossreactive antibodies against the proline-rich region of the
PspA could explain the high levels of recognition of the PspC
Figure 6 Schematicmodel of the proposed relationship betweenPneumococcal surface protein C (PspC), Factor H (FH), anti-PspC immunoglobulinG
(IgG), and pneumococcal adherence. (Left column) Untreated condition—noFHor other factors such as vitronectin are present. Adherence ismoderate.
(Middle column) In the presence of anti-PspC and low levels of FH there is decreased adherence because anti-PspC antibodies block pneumococcal
adherence to the epitheliummediated byother factors, such as vitronectin. Humananti-PspCantibodies do not recognize theFHbinding site of PspCand
therefore theFH–PspC interactionwith continue to facilitate low levels of pneumococcal adherence. (Right column) In the presence of anti-PspCandhigh
levels of FH there is increased adherence because of increased interactions of PspC–FH.
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proline-rich region in humans.34,35 We have previously
observed that colonization increased mucosal IgG antibodies
to the N-terminal region of PspA but not PspC.17 Most
importantly, the fact that humans have an inefficient pre-
sentation of the PspC region that binds to FH strongly suggests
that FH binding to pneumococcus during colonization covers
this site of the PspC antigen.
Our findings confirm previous reports that PspC is the
major, if not the only, protein that binds to FH. PspC–FH
interaction allows pneumococci to protect themselves from
the complement system36 as well as facilitate pneumococcal
adherence and uptake by human epithelial cells.37 Increased
adherence to lung epithelial cells was also reported when
pneumococci were preincubated with FH38 and could explain
the associated high burden of pneumonia following influenza
infections.39
Polymorphisms in the FH gene have been associated with
increased susceptibility to Staphylococcus aureus colonization
in humans.40 Binding to human FH has also been described as
an important host–pathogen interaction for Neisseria menin-
gitidis41 and a FH binding protein is a component in the first
licensed vaccine againstN.meningitidis serogroup B.42-44 Point
mutations that eliminate FH binding have been shown to
enhance protective antibody responses to vaccination using this
meningococcal FH binding protein.45 Our results support the
use of PspC as a mucosal vaccine candidate and highlight that
mutations in the FHbinding site that allow antibody generation
against this region should be considered for any vaccine
based on PspC. Blocking PspC–FH interaction with specific
PspC antibodies at the mucosa has the potential to reduce
viral-associated pneumococcal colonization and burden of
pneumonia associated with viral infections.
METHODS
EHPC study and pneumococcal detection. Healthy adult subjects
were enrolled with informed consent to an EHPC trial.13 All par-
ticipants were nonsmoking adults aged 18–60 years who had no close
contact with at-risk individuals, including young children (under the
age of 5 years) and the elderly (over 65 years with comorbidities).
Ethical approval was obtained from the National Health Service
Research Ethics Committee (11/nasal wash/0592 and 12/nasal
wash/0873) and the study was sponsored by the Royal Liverpool and
Broadgreen University Hospitals Trust.
Nasal wash samples were obtained 5 days before intranasal
inoculation with S. pneumoniae serotype 6B and then on days 2,
7, and 14 after inoculation. Inoculation doses were between 50 103
and 320 103 colony-forming units (CFUs) per 100ml. Bacterial
preparation, inoculation of subjects with 6B pneumococcus, nasal
wash sampling, carriage detection, and quantification of carriage
density were done as described previously.17
Detection and identification of URT virus. Oropharyngeal swabs
were collected 5 days before intranasal inoculation and immediately
put in viral transport medium (MWE, Corsham, UK). Viral multiplex
PCRwas performed as described elsewhere.46,47 Briefly, viral RNAwas
extracted from 200 ml of viral transport medium and eluted into 85 ml
buffer using the standard Pathogen Complex 200 protocol on the
QIAsymphony (QIAGEN, Crawley, UK). The eluates were then
analyzed using fourmultiplex PCR assays on the LC480 real-time PCR
machine (Roche Diagnostics, Burgess Hill, UK). The assay panel
covered the qualitative detection of influenza A and B, respiratory
syncytial virus, human metapneumovirus, human rhinovirus, para-
influenza viruses 1–4, and coronaviruses OC43, NL63, 229E, and
HKU1.
Levels of FH, lactoferrin, SLPI, and b-defensin 2 in nasal wash and
anti-PspC in sera samples. To measure levels of FH, 96-well plates
were coated with nasal wash samples serially diluted in carbonate–
bicarbonate buffer. Purified human FH (Calbiochem, Watford, UK)
was used as a standard. Goat anti-FH antibodies (Calbiochem)
followed by anti-goat IgG horseradish peroxidase-conjugated (R&D
Systems, Abingdon, UK) were used for detection before development
with TMB Substrate Reagent Set (BD, Oxford, UK). Levels of
lactoferrin (AssayPro, St Charles, MO), SLPI (R&D), and b-defensin 2
(Antigenix America, Huntington Station, NY) were measured by
sandwich ELISAs following the manufacturer’s recommendation.
Briefly, 96-well plates were coated with anti-human lactoferrin
(AssayPro) or SLPI (R&D). Plates were blocked with phosphate-
buffered saline (PBS)–1% bovine serum albumin before nasal wash
samples serially diluted in PBS–0.1% bovine serum albumin were
added. Human lactoferrin (AssayPro) and recombinant human SLPI
(R&D) were used as standards. Biotinylated rabbit anti-lactoferrin
or goat anti-SLPI followed by streptavidin-alkaline phosphatase
(AbDSerotec, Kidlington, UK)were used for detection before develop-
ment with 0.5mgml 1 of P-nitrophenyl phosphate. Absorbance
(450 nm) was measured for all assays using the FLUOstar OMEGA
plate reader (BMG Labtech, Aylesbury, UK). The b-defensin 2 levels
were measured using a kit as per the manufacturer’s instructions
(Antigenix America). Levels of anti-PspC IgG were measured by
ELISAs using plates coated with recombinant purified PspC and a
standard sera sample with known anti-PspC concentration as pre-
viously described using the last dilution of the sample with optical
density 40.1 to calculate the sample concentration.17 A four-para-
meter fit was used to generate the standard curve. All samples were run
in triplicate, and samples with coefficient of variation of415% were
repeated.
Depletion and purification of antibodies from nasal wash and sera
samples. Nasal wash samples from 10 subjects were pooled and IgG
and IgA were depleted by anti-human IgG and anti-human IgA
agarose (Sigma-Aldrich, Gillingham, UK), respectively. Samples were
incubated with agarose and flow-through fractions were used in
pneumococcal adherence assays. Dot blot assays were performed to
confirm antibody depletion (data not shown). Serum samples from
seven subjects were used for anti-PspC IgG purification. First, purified
total IgG was obtained from individual samples by HiTrap protein G
affinity column (GEHealthcare, Little Chalfont, UK). Purified samples
were then loaded in CNBr-activated Sepharose coupled with
recombinant purified PspC. Coupling (1mg of ligand PspC to 200mg
of sepharose) and anti-PspC purification was performed as per the
manufacturer’s instructions. To confirm anti-PspC IgG purification,
ELISAs were performed using plates coated with PspC as previously
described.17
Bacterial culture for invitroassays. D39 pneumococci were grown in
Todd Hewitt broth supplemented with 0.5% yeast extract (THY) at
37 1C in 5% CO2 until optical density 0.4–0.5 was reached. Bacteria
were either used immediately for flowbinding assays or resuspended in
THY 10% glycerol and stored at  80 1C for adherence assays.
FH binding and antibody binding assays. Bacterial stocks were
washed and resuspended in PBS. For inhibition of FH binding, 107
CFUs were resuspended in 100ml of individual nasal wash samples,
purified IgA and IgG samples (undiluted), or purified anti-PspC IgG
(1/2 diluted) and incubated for 45min at 37 1C. To evaluate the
saturating concentration of FH binding and for positive control of
inhibition of FH binding experiments, bacterial pellets were resus-
pended in 100ml of purified human FH (Calbiochem) (3 to
40 mgml 1) and incubated for 45min at 37 1C.
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Samples were washed with PBS and incubated in 100 ml of goat anti-
factor H (1/200) (Calbiochem) for 45min at 37 1C before wash and
incubation in 100 ml of FITC-conjugated anti-goat (1/500) (Sigma-
Aldrich) at 4 1C in the dark for 30min. Samples were washed twice and
resuspended in 500ml of PBS and 4% paraformaldehyde and stored at
4 1C before acquisition using a BD LSR II flow cytometer. A total of
20,000 bacterial events were acquired and samples were gated relative
to a negative control containing no anti-FH. Anti-PspC IgG binding
was evaluated by incubating bacterial pellets with individually purified
human anti-PspC IgG samples for 45min at 37 1C before detection
using anti-human IgG FITC antibody (1/10,000, Sigma-Aldrich). As
FH binding to S. pneumoniae is often biphasic48 with strongly positive
and weakly negative populations of bacteria, results are presented as
fluorescence index (percentage of positive bacteria multiplied by the
geometric mean fluorescence index in arbitrary units).
Pharyngeal epithelial cells and inflammation of epithelium. Detroit
562 pharyngeal epithelial cells (ATCC-CCL-138) were grown and
maintained at 90–100% confluence in T75 flasks (BD) in Eagle’s
minimal essential media (EMEM; Sigma-Aldrich) supplemented with
10% fetal bovine serum (Invitrogen, Paisley, UK), 2mM L-glutamine
(Sigma-Aldrich), 40Uml 1 penicillin, 40 mgml 1 streptomycin, and
80mgml 1 neomycin (Sigma-Aldrich) (complete media). Before
adherence experiments, cells were released using EDTA/trypsin (Invi-
trogen), washed with media, and a suspension of cells were seeded at
1 105 per ml in complete media in a 24-well plate (1ml per well). Cells
were ready for use in adherence experiments 3 or 4 days after seeding
(90% confluence). For inflamed epithelium, cells were stimulated with
interleukin-1b, tumornecrosis factor, and interferon-g (50ngml 1 each)
in 500ml of completeEMEMfor 16–18h at 37 1C5%CO2.Cellswere then
washed 3 times with warmed PBS and 500ml of EMEM without
antibiotics was added to each well before addition of pneumococci.
Epithelial polymeric immunoglobulin receptor and platelet-acti-
vating factor receptor expression by flow cytometry. Stimulated
(inflamed) and nonstimulated (noninflamed) cells were scraped from
the wells after washing with cold PBS. Cell suspensions were incubated
with platelet-activating factor receptor, human monoclonal antibody,
and polymeric immunoglobulin receptor rabbit polyclonal antibody
(both fromCambridge Bioscience, Cambridge, UK) at 4 1C for 15min.
Anti-human PE-conjugate and anti-rabbit FITC-conjugate antibodies
were added for 15min at 4 1C. Cells were washed and stored at 4 1C
before acquisition using a BD LSR II flow cytometer. A total of 10,000
gated events were recorded. PE goat anti-mouse IgG2a and FITC
donkey anti-rabbit IgG (both from Biolegend, London, UK) were used
as isotype controls.
Pneumococcal adherence and internalization assays. D39 bacterial
pellets were washed with PBS containing Ca2þ Mg2þ (Sigma-
Aldrich) before being resuspended anddiluted to 2 106CFUml 1 in
EMEM with no antibiotics. Bacterial suspensions were added to wells
containing D562 cells (500 ml per well), plates were gently shaken, and
20 ml was obtained from each well for dilution and initial CFU
quantification on blood agar plates (Oxoid, Basingstoke, UK). The 24-
well plates were then incubated at 37 1C 5% CO2 for 3 h. Wells were
washed 5 timeswith PBSCa2þ Mg2þ to remove unbound bacteria and
cells were either lysed with 1% saponin for 10min (for adherence) or
treatedwith 100 mgml 1 of ampicillin in EMEM (1ml per well) for 3 h
at 37 1C 5%CO2 before lysing (for internalization). Recovered bacteria
were quantified by serial dilution on blood agar plates. Plates were
incubated at 37 1C 5% CO2 overnight and initial and recovered CFUs
were counted. Averages of initial D39 CFU values were used to create a
correction factor so that the recovered CFUs for both strains could be
compared. All conditions were performed in duplicate and experi-
ments were performed at least twice. For each experiment, the average
recovered CFUs from the control condition (adherence of D39
untreated bacteria to noninflamed cells) was used to calculate fold
change for all remaining conditions.
Anti-PspC antibody epitope mapping. Overlapping peptide arrays
containing 15-mer peptides with a frameshift of four residues cor-
responding to the amino acid sequence of PspC3 (GenBank accession
no. EF424119) were synthesized in a slide support (CelluSpots, Intavis,
Cologne, Germany). Peptide arrays were incubated individually with
29 sera samples collected from 18 subjects inoculated with pneu-
mococcus or from mice immunized with 3 doses of 5 mg of PspC3
containing 50 mg of Alum as previously described.49 Concentration of
pneumococcal-specific antibodies was standardized so that each
sample used for incubation contained 10 mgml 1 of PspC IgG.
Detection was performed using alkaline phosphatase-conjugated
anti-mouse IgG and anti-human IgG (Sigma-Aldrich). MTT 0.12M
(Methylthiazolyldiphenyl-tetrazoliumbromide), BCIP0.16M(5-Bromo-
4-chloro-3-indolyl phosphate), and MgCl2 1M in citrate-buffered saline
pH 7.0 was used for development.
Statistical analysis. Fisher’s exact test was used to compare
the proportion of carriers that were virus positive and virus negative.
Pearson’s correlation coefficient was used to compare log-transformed
FH levels and pneumococcal carriage density. Flow cytometry data
were analyzed using Flow Jo v7.6.1 (Tree Star, Ashland, OR). To
account for possible correlation among the repeated measurements
in carriage status and density, GEE model was employed for the data
analysis. For the GEE analysis of carriage presence (yes or no),
binomial distribution and logit link function were used. For the
GEE analysis of carriage density, log-transformed density was
used as the dependent variable and normal distribution and
identity link function were used. Three GEE models were estimated
to assess the effects of FH levels and virus status on carriage
status and density, separately and jointly. Model 1 has virus status
(positive and negative) and day (days 2, 7, and 14) as predictors; model
2 has FH levels in log scale and day as predictors; model 3 has FH levels
and virus status, day, and interaction between FH levels and virus
as predictors.
Differences were considered significant if Pr0.05. Statistical
analyses and graphical presentations were performed using Graphpad
Prism5 (La Jolla, CA) and SAS9.3 (Cary, NC).
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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